|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jazieh AR, Bamefleh H, Demirkazik A, et
al: Modification and implementation of NCCN guidelines on non-small
cell lung cancer in the Middle East and North Africa region. J Natl
Compr Canc Netw. 8:(Sul 3). S16–S21. 2010.PubMed/NCBI
|
|
3
|
Lynch TJ, Bell DW, Sordella R,
Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat
SM, Supko JG, Haluska FG, et al: Activating mutations in the
epidermal growth factor receptor underlying responsiveness of
non-small-cell lung cancer to gefitinib. N Engl J Med.
350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Taron M, Ichinose Y, Rosell R, Mok T,
Massuti B, Zamora L, Mate JL, Manegold C, Ono M, Queralt C, et al:
Activating mutations in the tyrosine kinase domain of the epidermal
growth factor receptor are associated with improved survival in
gefitinib-treated chemorefractory lung adenocarcinomas. Clin Cancer
Res. 11:5878–5885. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gazdar AF and Minna JD: Inhibition of EGFR
signaling: All mutations are not created equal. PLoS Med.
2:e3772005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hirsch FR: EGFR: a prognostic and/or a
predictive marker? J Thorac Oncol. 1:395–397. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Dacic S, Flanagan M, Cieply K, Ramalingam
S, Luketich J, Belani C and Yousem SA: Significance of EGFR protein
expression and gene amplification in non-small cell lung carcinoma.
Am J Clin Pathol. 125:860–865. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Downward J: Targeting RAS signalling
pathways in cancer therapy. Nat Rev Cancer. 3:11–22. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Pao W, Wang TY, Riely GJ, Miller VA, Pan
Q, Ladanyi M, Zakowski MF, Heelan RT, Kris MG and Varmus HE: KRAS
mutations and primary resistance of lung adenocarcinomas to
gefitinib or erlotinib. PLoS Med. 2:e172005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Li J, Li ZN, Yu LC, Bao QL, Wu JR, Shi SB
and Li XQ: Association of expression of MRP1, BCRP, LRP and ERCC1
with outcome of patients with locally advanced non-small cell lung
cancer who received neoadjuvant chemotherapy. Lung Cancer.
69:116–122. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Azuma K, Sasada T, Kawahara A, Takamori S,
Hattori S, Ikeda J, Itoh K, Yamada A, Kage M, Kuwano M, et al:
Expression of ERCC1 and class III beta-tubulin in non-small cell
lung cancer patients treated with carboplatin and paclitaxel. Lung
Cancer. 64:326–333. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Burkhart CA, Kavallaris M and Band Horwitz
S: The role of beta-tubulin isotypes in resistance to antimitotic
drugs. Biochim Biophys Acta. 1471:O1–O9. 2001.PubMed/NCBI
|
|
13
|
Bepler G, Sommers KE, Cantor A, Li X,
Sharma A, Williams C, Chiappori A, Haura E, Antonia S, Tanvetyanon
T, et al: Clinical efficacy and predictive molecular markers of
neoadjuvant gemcitabine and pemetrexed in resectable non-small cell
lung cancer. J Thorac Oncol. 3:1112–1118. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Rosell R, Danenberg KD, Alberola V, Bepler
G, Sanchez JJ, Camps C, Provencio M, Isla D, Taron M, Diz P, et al:
Spanish Lung Cancer Group: Ribonucleotide reductase messenger RNA
expression and survival in gemcitabine/cisplatin-treated advanced
non-small cell lung cancer patients. Clin Cancer Res. 10:1318–1325.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Travis W, Colby TV and Corrin B:
Histologic Typing of Tumors of Lung and Pleura: World Health
Organization International Classification of Tumors. 3rd. Springer
Verlag; New York, NY: 1999
|
|
16
|
Li G, Luo X, He J, Zhu Z, Yu G, Qin H,
Zeng T, Liu Z, Wu S, Xu J, et al: A novel liquidchip platform for
simultaneous detection of 70 alleles of DNA somatic mutations on
EGFR, KRAS, BRAF and PIK3CA from formalin-fixed and
paraffin-embedded slides containing tumor tissue. Clin Chem Lab
Med. 49:191–195. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang Y, Liu ZD, Zhao LM, Du CX, Xi XM, Mi
YL, Peng Y, Li WG, Cheng F, Zhang XR, et al: Individualized
treatment of NSCLC: From research to clinical practice. Neoplasma.
60:538–545. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sharma SV, Bell DW, Settleman J and Haber
DA: Epidermal growth factor receptor mutations in lung cancer. Nat
Rev Cancer. 7:169–181. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mitsudomi T and Yatabe Y: Mutations of the
epidermal growth factor receptor gene and related genes as
determinants of epidermal growth factor receptor tyrosine kinase
inhibitors sensitivity in lung cancer. Cancer Sci. 98:1817–1824.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hirsch FR, Varella-Garcia M, Bunn PA Jr,
Franklin WA, Dziadziuszko R, Thatcher N, Chang A, Parikh P, Pereira
JR, Ciuleanu T, et al: Molecular predictors of outcome with
gefitinib in a phase III placebo-controlled study in advanced
non-small-cell lung cancer. J Clin Oncol. 24:5034–5042. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Vadakara J and Borghaei H: Personalized
medicine and treatment approaches in non-small-cell lung carcinoma.
Pharmgenomics Pers Med. 5:113–123. 2012.PubMed/NCBI
|
